MARKHAM, ON, Sept. 8 /PRNewswire/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the following investor conferences:
- Baird's 2010 Health Care Conference at 10:30 AM EDT on Tuesday, September 14, 2010 at The St. Regis New York in New York City. - Stifel Nicolaus Healthcare Conference 2010 at 10:55 AM EDT on Friday, September 17, 2010 at the Four Seasons Hotel in Boston.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD patients, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD patients. Cytochroma also has a portfolio of compounds that inhibit CYP24 in early stage development.